These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 2527128)
1. The effect of improved control on blood filtration properties and non-enzymatic glycosylation of erythrocyte proteins in type 2 diabetes. Yue DK; Capogreco C; McLennan SV; Turtle JR Diabet Med; 1989 Aug; 6(6):486-9. PubMed ID: 2527128 [TBL] [Abstract][Full Text] [Related]
2. The association between erythrocyte internal viscosity, protein non-enzymatic glycosylation and erythrocyte membrane dynamic properties in juvenile diabetes mellitus. Watala C; Witas H; Olszowska L; Piasecki W Int J Exp Pathol; 1992 Oct; 73(5):655-63. PubMed ID: 1329916 [TBL] [Abstract][Full Text] [Related]
3. The effects of in vivo and in vitro non-enzymatic glycosylation and glycoxidation on physico-chemical properties of haemoglobin in control and diabetic patients. Watala C; Golański J; Witas H; Gurbiel R; Gwoździński K; Trojanowski Z Int J Biochem Cell Biol; 1996 Dec; 28(12):1393-403. PubMed ID: 9022296 [TBL] [Abstract][Full Text] [Related]
4. A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy. Wolffenbuttel BH; Weber RF; van Koetsveld PM; Weeks L; Verschoor L Diabet Med; 1989 Aug; 6(6):520-5. PubMed ID: 2527134 [TBL] [Abstract][Full Text] [Related]
5. Impairment of erythrocyte viscoelasticity is correlated with levels of glycosylated haemoglobin in diabetic patients. Symeonidis A; Athanassiou G; Psiroyannis A; Kyriazopoulou V; Kapatais-Zoumbos K; Missirlis Y; Zoumbos N Clin Lab Haematol; 2001 Apr; 23(2):103-9. PubMed ID: 11488849 [TBL] [Abstract][Full Text] [Related]
6. Oxidation of spectrin and deformability defects in diabetic erythrocytes. Schwartz RS; Madsen JW; Rybicki AC; Nagel RL Diabetes; 1991 Jun; 40(6):701-8. PubMed ID: 2040386 [TBL] [Abstract][Full Text] [Related]
7. Nonenzymatic protein glycosylation. I. Lowered erythrocyte membrane fluidity in juvenile diabetes. Watała C; Zawodniak M; Bryszewska M; Nowak S Ann Clin Res; 1985; 17(6):327-30. PubMed ID: 4096489 [TBL] [Abstract][Full Text] [Related]
8. Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. Murugan P; Pari L J Ethnopharmacol; 2007 Sep; 113(3):479-86. PubMed ID: 17693046 [TBL] [Abstract][Full Text] [Related]
9. Studies on glycosylated plasma proteins in diabetic patients. Rehman J; Rahman MA J Pak Med Assoc; 1991 Jan; 41(1):16-8. PubMed ID: 1900545 [TBL] [Abstract][Full Text] [Related]
10. No decreased erythrocyte deformability in type 1 (insulin-dependent) diabetes, either by filtration or by ektacytometry. Schut NH; van Arkel EC; Hardeman MR; Bilo HJ; Michels RP; Vreeken J Acta Diabetol; 1993; 30(2):89-92. PubMed ID: 8219264 [TBL] [Abstract][Full Text] [Related]
11. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977 [TBL] [Abstract][Full Text] [Related]
12. Erythrocyte fragility increases with level of glycosylated hemoglobin in type 2 diabetic patients. Kung CM; Tseng ZL; Wang HL Clin Hemorheol Microcirc; 2009; 43(4):345-51. PubMed ID: 19996523 [TBL] [Abstract][Full Text] [Related]
13. Improvement of diabetic or obese patients' erythrocyte deformability by the program of the brain-oriented obesity control system (BOOCS). Saito K; Odashiro K; Maruyama T; Akashi K; Mawatari S; Fujino T J Physiol Sci; 2012 Nov; 62(6):445-51. PubMed ID: 22843251 [TBL] [Abstract][Full Text] [Related]
14. Diabetic control with gliquidone--a short acting sulphonylurea. Borthwick LJ; Wilson S Eur J Clin Pharmacol; 1984; 26(4):475-9. PubMed ID: 6428917 [TBL] [Abstract][Full Text] [Related]
15. Erythrocyte membrane fluidity as a marker of diabetic retinopathy in type 1 diabetes mellitus. Bianchetti G; Viti L; Scupola A; Di Leo M; Tartaglione L; Flex A; De Spirito M; Pitocco D; Maulucci G Eur J Clin Invest; 2021 May; 51(5):e13455. PubMed ID: 33210748 [TBL] [Abstract][Full Text] [Related]
16. The relationship of chemical modification of membrane proteins and plasma lipoproteins to reduced membrane fluidity of erythrocytes from diabetic subjects. Watala C; Winocour PD Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):513-9. PubMed ID: 1457612 [TBL] [Abstract][Full Text] [Related]
17. Erythrocyte deformability in diabetes and erythrocyte membrane lipid composition. Garnier M; Attali JR; Valensi P; Delatour-Hanss E; Gaudey F; Koutsouris D Metabolism; 1990 Aug; 39(8):794-8. PubMed ID: 2377077 [TBL] [Abstract][Full Text] [Related]
18. Effect of mulberry (Morus indica L.) therapy on plasma and erythrocyte membrane lipids in patients with type 2 diabetes. Andallu B; Suryakantham V; Lakshmi Srikanthi B; Reddy GK Clin Chim Acta; 2001 Dec; 314(1-2):47-53. PubMed ID: 11718678 [TBL] [Abstract][Full Text] [Related]
19. [Evaluation of erythrocyte survival by the determination of glycosylated hemoglobin. Clinical value]. Rigal D; Monestier M; Baboin-Jaubert M; Chabaud-Sassoulas D; Marseglia GL; Ville D; Meyer F; Jouvenceaux A Presse Med; 1985 Mar; 14(9):521-3. PubMed ID: 3157163 [TBL] [Abstract][Full Text] [Related]
20. Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients. Miossec P; Zkhiri F; Pariès J; David-Dufilho M; Devynck MA; Valensi PE Diabet Med; 1999 May; 16(5):424-30. PubMed ID: 10342343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]